Alchemia Announces Quarterly Fondaparinux Profit Share
February 19, 2014 06:00 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Feb 19, 2014) - Alchemia Limited (ASX: ACL), a drug discovery and development company, today reports profit share of A$2.8 million (US$2.5 million) for the...
Nexvet Biopharma to Present at the Cowen and Company 34th Annual Health Care Conference on March 5, 2014
February 18, 2014 06:00 ET
|
Nexvet Biopharma
MELBOURNE, AUSTRALIA--(Marketwired - Feb 18, 2014) - Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that Dr Mark Heffernan, Nexvet's Chief Executive Officer, is...
Alchemia Announces Half-Year Results for Period Ended 31 December 2013
February 18, 2014 06:00 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Feb 18, 2014) - Alchemia Limited, (ASX: ACL) a drug discovery and development company, is pleased to announce its half year results for the six months ended 31...
Genetic Technologies Announces Update on Intellectual Property
February 12, 2014 12:25 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Feb 12, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the...
Alchemia Announces Appointment of Santo J. Costa as Chairman
February 11, 2014 05:30 ET
|
Alchemia
BRISBANE, AUSTRALIA--(Marketwired - Feb 11, 2014) - Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced the appointment of Santo J. Costa as non-executive...
Genetic Technologies Provides Corporate and Financial Update for Quarter Ended December 31, 2013
January 30, 2014 10:42 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Jan 30, 2014) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE)
Total sales revenue for BREVAGen™ test increased 50%...
Genetic Technologies Announces New Record Growth in Number of BREVAGen(TM) Tests Received for December Quarter
January 08, 2014 05:15 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Jan 8, 2014) - Genetic Technologies Limited (NASDAQ: GENE) (ASX: GTG) today announced that a new record number of BREVAGen™ test samples were received...
Genetic Technologies Announces Issue of Redeemable Convertible Note and Receipt of Funds
December 23, 2013 09:06 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Dec 23, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that the Redeemable Convertible Note (the "Note") described in the...
Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
December 18, 2013 13:57 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Dec 18, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest...
Genetic Technologies Announces Publication Highlighting Cost-Effectiveness of BREVAGen(TM) in Cancer Prevention Research
December 06, 2013 05:15 ET
|
Genetic Technologies
MELBOURNE, AUSTRALIA--(Marketwired - Dec 6, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced its flagship genetic breast cancer risk prediction test, BREVAGen™,...